PUBLISHER: The Business Research Company | PRODUCT CODE: 2040088
PUBLISHER: The Business Research Company | PRODUCT CODE: 2040088
Skyrizi is a prescription biologic medicine containing risankizumab, a humanized monoclonal antibody that selectively inhibits interleukin-23 (IL-23), a key cytokine involved in inflammatory and immune responses. It is administered by injections and is approved for the treatment of immune-mediated inflammatory diseases, most notably moderate to severe plaque psoriasis. The primary purpose of skyrizi is to reduce inflammation and control disease symptoms by targeting a specific immune pathway rather than broadly suppressing the immune system.
The skyrizi market consists of sales by entities (organizations, sole traders and partnerships) of skyrizi that is typically used on a long-term basis, with dosing intervals varying by disease indication and treatment stage. It complements or substitutes other biologic drugs such as adalimumab, ustekinumab, and infliximab, as well as non-biologic systemic treatments like corticosteroids and immunosuppressants.
The global skyrizi market was valued at $1,590.0 million in 2020 which grew till 2025 at a compound annual growth rate (CAGR) of more than 54.00%.
Rise In Patient Access Programs
During the historic period, the skyrizi market was significantly driven by the rise in patient access programs. As healthcare systems increasingly adopted digital health infrastructure and patient-centric access frameworks, a growing proportion of individuals became more actively involved in managing chronic conditions, monitoring treatment progress, and participating in long-term care decisions. For instance, in September 2025, according to a HealthIT.gov data brief, U.S. hospitals significantly expanded patient access and engagement capabilities between 2021 and 2024, with the share of hospitals adopting all foundational electronic access functions (view, download, transmit, messaging) rising from 72 % in 2021 to 80 % in 2024. Emerging capabilities such as access to clinical notes and app-based health information use also increased from 65 % to 85 % over the same period. Advanced patient access tools like record import and patient-generated data submission grew from 37 % to 45 %. By 2024, nearly all hospitals enabled patients to view (99 %) and download (96 %) their health records electronically, and 92 % supported secure provider messaging. Therefore, the skyrizi market was significantly driven by the rise in patient access programs during the historic period.
Expanding Regulatory Approvals For IL-23 Inhibitors
Companies in the skyrizi market are focusing on expanding regulatory approvals for IL-23 inhibitors to strengthen skyrizi's position across multiple immune-mediated inflammatory diseases. Broader approvals enable access to larger and more diverse patient populations, including those with limited response to existing biologics. This expansion enhances physician adoption by positioning skyrizi as a versatile, disease-modifying therapy. Additionally, multi-indication approvals support sustained market growth by extending product lifecycle and reinforcing competitive differentiation. For example, in June 2024, AbbVie, a US-based pharmaceutical company, announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI(R) (risankizumab-rzaa) for adults with moderately to severely active ulcerative colitis, making it the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn's disease.3 SKYRIZI is now approved for four indications across immune-mediated inflammatory diseases.
The global skyrizi market is highly concentrated, with large players operating in the market. The top competitors in the market made up to 100.0% of the total market in 2024.
Skyrizi Global Market Opportunities And Strategies To 2035 from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global skyrizi market as it emerges from the COVID-19 shut down.
Where is the largest and fastest-growing market for skyrizi? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The skyrizi market global report from The Business Research Company answers all these questions and many more. The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider skyrizi market, and compares it with other markets.